All In Biotech

NDA 018602 · Bausch

Cardizem

Diltiazem Hydrochloride · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Nov 5, 1982

Approved uses

4

Original approval plus efficacy supplements

Registered trials

127

21 Phase 3, 6 recruiting

FAERS reports

23,272

17,790 serious, 4,039 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 30, 2025.

INDICATIONS AND USAGE CARDIZEM is indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Mechanism: Mechanisms of Action Although precise mechanisms of its antianginal actions are still being delineated, CARDIZEM is believed to act in the following ways: Angina Due to Coronary Artery Spasm: CARDIZEM has been shown to be a potent dilator of coronary arteries both epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery spasms are inhibited by CARDIZEM. Exertional Angina: CARDIZEM has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and systemic...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 1, 1993 Supplement 23 · Efficacy
  • Dec 8, 1986 Supplement 20 · Efficacy
  • Jul 28, 1986 Supplement 11 · Efficacy
  • Nov 5, 1982 Original approval · Type 1 - New Molecular Entity
4 products under this application
  • CARDIZEM · DILTIAZEM HYDROCHLORIDE 90MG · TABLET, ORAL · Prescription · TE AB
  • CARDIZEM · DILTIAZEM HYDROCHLORIDE 30MG · TABLET, ORAL · Prescription · TE AB
  • CARDIZEM · DILTIAZEM HYDROCHLORIDE 120MG · TABLET, ORAL · Prescription · TE AB
  • CARDIZEM · DILTIAZEM HYDROCHLORIDE 60MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Diltiazem" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea2,392
  • fatigue2,001
  • pain1,858
  • nausea1,717
  • dizziness1,638
  • diarrhoea1,549
  • fall1,526
  • headache1,486
  • drug ineffective1,458
  • arthralgia1,291
  • atrial fibrillation1,262
  • asthenia1,237

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004837
2005894
2006759
2007579
2008568
2009649
2010920
2011966
2012981
2013865
2014988
20151,179
20161,196
20171,073
2018960
2019894
2020956
20211,146
20221,687
20231,288
20241,524
20251,457
2026905

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cardizem (Diltiazem HCl)

2024 spending

$144K

Beneficiaries

34

96 claims

Per beneficiary

$4,241

$8.51 per unit

View as table
YearSpending
2020$447,835
2021$363,921
2022$305,394
2023$224,141
2024$144,190

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,211 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.